Foresite Capital Opportunity Management V, LLC
CIK 1792207
13F portfolio (2022-Q3)
$33M
Positions
9
As reported on this filer's Form 13F for 2022-Q3, filed 2022-11-14. Long positions in SEC Section 13(f) securities; a lagged quarterly snapshot, filed up to 45 days after quarter-end. This filer has stopped filing 13F reports.
| 1 | PRDS | PARDES BIOSCIENCES INC |
| 2 | THRX | THESEUS PHARMACEUTICALS INC |
| 3 | — | GEMINI THERAPEUTICS INC |
| 4 | CMPX | COMPASS THERAPEUTICS INC |
| 5 | KNTE | KINNATE BIOPHARMA INC |
Top holdings — weights and history with Pro
This 13F filer is outside the free plan's window — the 50 largest filers by portfolio value plus our curated roster of managers. It is in neither group. Unlock everything with Pro — $29.99/moSee it live on AAPL →